Back to today’s briefing

Story perspectives

Fifth Third Cuts Myriad Stake Amid Quarterly Loss

1/30/2025

48 4

Summary

Story summary

Fifth Third Bancorp has trimmed its investment in Myriad Genetics by nearly 30%, now holding 55,315 shares worth $758,000. Meanwhile, Loomis Sayles & Co. has ramped up its stake. Analysts maintain a "Hold" rating for Myriad, with a price target of $22.83, as the company faces a recent quarterly loss of $0.06 EPS.

1 of 1

Story summary

Fifth Third Bancorp has trimmed its investment in Myriad Genetics by nearly 30%, now holding 55,315 shares worth $758,000. Meanwhile, Loomis Sayles & Co. has ramped up its stake. Analysts maintain a "Hold" rating for Myriad, with a price target of $22.83, as the company faces a recent quarterly loss of $0.06 EPS.